Shenzhen KeYe Life Technologies

Shenzhen KeYe Life Technologies is a biotechnology company focused on the development of innovative cell therapies, particularly chimeric antigen receptor T-cell (CAR-T) treatments. The company targets both hematological malignancies and challenging solid tumors, such as liver cancer, by leveraging its proprietary cell engineering platforms. KeYe's research emphasizes improving the safety and durability of immune cell products to address unmet medical needs in oncology. Based in Shenzhen's biotech hub, the firm integrates R&D with clinical translation to accelerate the delivery of next-generation immunotherapies. Their lead programs are currently advancing through early-stage clinical trials in China.